There are a few conditions that would make a medication unsafe for a patient to take, when it comes to GLP-1s and GLP/GIP medications
That flexibility matters because tirzepatide tends to produce stronger average weight loss for some patients, while others prefer semaglutide or want to avoid injections entirely
One study examining the effects of the GLP-1 liraglutide, for example, found that the medication improved insulin sensitivity within two weeks, prior to weight loss, in people who have obesity and prediabetes, but other research has found that GLP-1s only have minimal direct benefits on insulin sensitivity
They are the concentrations most researchers choose precisely because the math works out to whole numbers or easy fractions on an insulin syringe
PMID: 42231627 In Vitro Cell Dev Biol Anim Liraglutide ameliorates high glucose-induced vascular endothelial injury through TRIB3/NF-B signaling pathway
But you can microdose by spacing them out longer (e.g., every 10 days or two weeks)